Generally, DM is caused by insufficient insulin secretion in the body; however, the other biological mechanisms remain unclear. Long-term illness in patients with DM damages various organs in the body, such as the eyes, kidneys, and heart, seriously affecting organ function. Nowadays, the quality of life of people has improved significantly, eating habits have changed, sugar intake is increasing, and the number of patients with DM is increasing. Statistics show that in 2017, the number of patients with DM worldwide reached 425 million (aged 20-79 years), which will exceed 600 million in 30 years; moreover, patients in low- and middle-income countries, such as China and India, account for 80 percent of the total DM population (1). According to the WHO, patients with DM worldwide increased to 366 million in 2011, which is expected to increase to 500 million in 2025, with more than 150 million patients experiencing ocular complications, such as diabetic retinopathy (DR) (2, 3). DR is a form of ocular microangiopathy and the most serious DM-related complication; it seriously endangers the health of patients with DM (4). DR pathogenesis includes increased endothelial cells in the eye capillaries, increased intimal thickness, damaged pericytes, microangioma, and damaged blood-retina barrier due to increased permeability of the blood vessels, microvascular obstruction, and neovascularization (NV) (5, 6). Currently, the prevalence of DR is 34.6% worldwide; however, it is higher in some developed countries, reaching 40.3% (7). The proportion of patients with type 1 and 2 DM suffering from blindness due to DR is 3.6% and 1.6%, respectively (8). DR is associated with significantly reduced living standards, huge medical costs, and increased social burden (9, 10).
Many anti-vascular endothelial growth factor (VEGF) drugs exist; however, the use of therapeutic drugs is strictly controlled. The main drugs recommended for treating DM-related visual complications are ranibizumab and aflibercept.

Start Date19 Oct 2025

Sponsor / Collaborator

Tanta University

NCT06470373

/ Not yet recruitingPhase 3

A Phase 3 Clinical Trial to Compare Efficacy, Safety, Tolerability and Immunogenicity of RBS-001 to Eylea® in Subjects With Neovascular Age-Related Macular Degeneration

This clinical study is designed to demonstrate the equivalence of the two Investigational Products by comparing the efficacy, safety, tolerability and immunogenicity of RBS-001 and Eylea® in subjects with Neovascular age-related macular degeneration.

Start Date01 Jul 2025

Sponsor / Collaborator

Rophibio Co., Ltd

NCT06769412

/ Not yet recruitingNot Applicable

Incidence of Retinal Vasculitis Among Patients Receiving Aflibercept 2 mg: A US Real-World Evidence Study Using the IRIS Registry

This study will describe and estimate the incidence of RV events among patients and patient eyes receiving aflibercept intravitreal (IVT) (Eylea® 2mg) therapy in US clinical practice. This study will also use clinical record review to confirm cases of RV first identified using International Classification of Diseases, tenth revision, Clinical Modification (ICD-10-CM) codes and to identify RV with occlusion.

Start Date15 Apr 2025

Sponsor / Collaborator

Regeneron Pharmaceuticals, Inc.

100 Clinical Results associated with Aflibercept

100 Translational Medicine associated with Aflibercept

100 Patents (Medical) associated with Aflibercept

3,530

Literatures (Medical) associated with Aflibercept

31 Dec 2025·DRUG DELIVERY

Safety and biocompatibility of a novel biodegradable aflibercept-drug delivery system in rhesus macaques

Article

Author: Mieler, William F. ; Shim, Jaeho ; Kang-Mieler, Jennifer J. ; Story, Brett D. ; Rudeen, Kayla M. ; Thomasy, Sara M. ; Ferneding, Michelle ; Motta, Monica ; Blandino, Andrew ; Ardon, Monica ; Teixeira, Leandro B. C. ; Roszak, Karolina ; Yiu, Glenn ; Park, Sangwan ; Le, Sophie

A clinical need exists for more effective intravitreal (IVT) drug delivery systems (DDS). This study tested the hypothesis that a novel biodegradable, injectable microsphere-hydrogel drug delivery system loaded with aflibercept (aflibercept-DDS) would exhibit long-term safety and biocompatibility in a non-human primate (NHP) model. We generated aflibercept-loaded poly (lactic-co-glycolic acid) microparticles with a modified double emulsion technique then embedded them into a biodegradable, thermo-responsive poly (ethylene glycol)-co-(L-lactic-acid) diacrylate/N-isopropylacrylamide hydrogel. Aflibercept-DDS (50 µL, 15 µg) was injected into the right eye of 23 healthy rhesus macaques. A complete ophthalmic examination, intraocular pressure (IOP), corneal pachymetry, specular microscopy, A-scan biometry, streak retinoscopy, spectral-domain optical coherence tomography (SD-OCT), fluorescein angiography (FA), and electroretinography (ERG) were performed monthly. Globes from 7 NHPs were histologically examined. Aflibercept-DDS was visualized in the vitreous up to 9 months post-IVT injection, slightly impeding fundoscopy in 4 of 23 eyes; no other consistent abnormalities were appreciated during ophthalmic examination. The IOP and total retinal thickness remained normal in all animals over all timepoints. Central corneal thickness, endothelial cell density, axial globe length, and refractive error did not significantly differ from baseline. Scotopic mixed rod-cone implicit times and amplitudes along with photopic cone response implicit times and amplitudes did not significantly differ from control values. No retinal or choroidal vascular abnormalities were detected with FA and normal retinal architecture was preserved using SD-OCT. Intravitreal injection of a biodegradable aflibercept-DDS was safe and well tolerated in NHPs up to 24 months.

31 Dec 2025·JOURNAL OF MEDICAL ECONOMICS

Cost-effectiveness analysis of bispecific antibody faricimab for treatment of neovascular age-related macular degeneration and diabetic macular edema in Japan

Article

Author: Igarashi, Ataru ; Sakashita, Naotaka ; Shoji, Ayako ; Higashi, Kentaro ; Tsujimura, Jun ; Ohno, Shinya ; Yanagi, Yasuo

OBJECTIVE:

To assess the cost-effectiveness of faricimab vs. other anti-vascular endothelial growth factor (anti-VEGF) drugs for treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) in Japan, while considering societal burden associated with treatment.

METHODS:

A Markov model for cost-effectiveness analysis of anti-VEGF treatment in patients with nAMD and DME was applied based on cost and utility value data from Japan. Faricimab administered through a treat-and-extend (T&E) regimen was compared with ranibizumab administered pro re nata (PRN) and T&E, aflibercept T&E, brolucizumab T&E, and best supportive care (BSC). Further to treatment costs (public payer perspective), the societal burden (societal perspective), including costs of travel, informal care, and productivity, was assessed.

RESULTS:

In treatment of nAMD, lifetime quality-adjusted life years (QALYs) gained were highest with faricimab (faricimab T&E: 6.92, ranibizumab PRN: 6.88, ranibizumab T&E: 6.91, aflibercept T&E: 6.89, brolucizumab T&E: 6.89, BSC: 5.99). From the public payer perspective, the lifetime total cost for faricimab T&E was lower than those for ranibizumab (PRN, T&E) and brolucizumab (T&E), comparable to aflibercept T&E, and higher than BSC (incremental costs: 158,385 and 6,475,511 JPY, respectively). As a result, faricimab was cost-effective or dominant in the treatment of nAMD, excluding BSC. From the societal perspective, faricimab was dominant against all comparators in nAMD. In treatment of DME, QALYs gained were highest with faricimab (faricimab T&E: 8.51, ranibizumab PRN: 8.17, aflibercept PRN: 8.36, ranibizumab T&E: 8.13, BSC: 5.16). From both the public payer and societal perspectives, faricimab was dominant against all comparators in DME.

CONCLUSIONS:

When societal burdens were considered, faricimab was dominant in both nAMD and DME against all comparators, suggesting that the extended dosing interval associated with faricimab treatment may alleviate societal burdens and consequently improve patient outcomes.

01 Jun 2025·Molecular Therapy-Methods & Clinical Development

Enhanced retinal pigment epithelial cells as a delivery vehicle for retinal disease

Article

Author: Adamson, Peter ; Hudson, Natalie ; Kiang, Anna-Sophia ; Greene, Chris ; Reddy, Avril ; Hashimoto, Yosuke ; Campbell, Matthew ; Santos-Ferreira, Tiago

Age-related macular degeneration (AMD) represents a major global health burden, with current estimates suggesting that up to 200 million people are affected globally. While effective treatments exist for the exudative form of the disease termed choroidal neovascular AMD, there remain challenges associated with long-term responses to treatment and the ongoing parallel development of the non-exudative form of AMD. Here, we sought to develop an approach for long-term delivery of both aflibercept, a decoy receptor that neutralises vascular endothelial growth factor and a concomitant treatment focused on treating the non-exudative form of AMD. To this end, we developed a series of induced pluripotent stem cell (iPS)-derived retinal pigment epithelial (RPE) cell lines that stably expressed aflibercept and/or sCD59. These cell lines were shown to produce high concentrations of both proteins. Sub-retinal injection of enhanced RPE cells potently prevented leakage of neovascular lesions in the JR5558 mouse model of retinal and choroidal neovascularization. Early results described here suggest that enhanced iPS-derived RPE cells could represent a novel approach to the long-term delivery of therapeutic agents to the eye.

592

News (Medical) associated with Aflibercept

23 Apr 2025

·www.globenewswire.com

UNITY Biotechnology Announces Publication in NEJM Evidence Highlighting the Potential of Senolytic Therapeutics to Provide Long-Term Improvements in Vision in DME

SOUTH SAN FRANCISCO, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, today announced that the peer-reviewed journal NEJM Evidence published results from the Phase 2 BEHOLD study of UBX1325 in patients with diabetic macular edema (DME). As reported in the article titled, “Safety and Efficacy of Senolytic UBX1325 in Diabetic Macular Edema,” the results suggested that the selective clearance of senescent cells in the retina provided disease-modifying and long-lasting improvements in vision in patients with DME, supporting the potential of UBX1325 as a novel modality for retinal diseases. “By targeting senescent cells, we expect to remodel the retinal vasculature, which should lead to improvements in retinal function,” said Anirvan Ghosh, Ph.D., chief executive officer of UNITY and an author of the paper. “We see the impact of this approach in action in the BEHOLD study, in which patients experienced meaningful and sustained improvements in their visual acuity for 1 year after a single injection of UBX1325. By selectively targeting an underlying cause of inflammation and disease progression, senolytic therapies could provide a valuable future treatment option for DME patients.” As previously disclosed and presented at the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting, a single injection of the senolytic candidate UBX1325 led to a statistically significant and clinically meaningful improvement in vision with extended durability through 48 weeks in patients with advanced DME. UNITY is currently conducting a Phase 2b ASPIRE study to evaluate multiple doses of UBX1325 in a head-to-head comparison to aflibercept. Topline 24-week and 36-week data was disclosed on March 24, 2025 and full 36-week data is expected in the second quarter of 2025. About the BEHOLD StudyThe proof-of-concept Phase 2 BEHOLD study is a multi-center, randomized, double-masked, sham-controlled study designed to evaluate the safety, tolerability, efficacy and durability of a single 10 mcg dose of UBX1325 in patients with DME. The study enrolled 65 patients who, despite being on anti-VEGF treatment for at least 6 months, displayed persistent visual acuity deficits (73 ETDRS letters, approximately 20/40, or worse) and residual retinal fluid (CST ≥300 microns). At baseline, patients in the study had an average visual acuity of 61.4 ETDRS letters and a CST of approximately 439.6 microns. In the 6 months prior to study enrollment, patients received an average of 4 anti-VEGF injections, with the last anti-VEGF injection occurring 3-6 weeks prior to randomization. Fifty patients completed the 48-week study extension. More information about the study is available here (NEJM Evidence) and here. About UBX1325 UBX1325 is an investigational compound being studied in retinal diseases, including DME, and is not approved for any use in any country. UBX1325 is a potent small molecule inhibitor of BCL-xL, a member of the BCL-2 family of apoptosis regulating proteins. UBX1325 is designed to inhibit the function of proteins that senescent cells rely on for survival. The Phase 2 BEHOLD study in patients with DME demonstrated that a single injection of UBX1325 resulted in a statistically significant and clinically meaningful improvement in mean BCVA through 48 weeks compared to sham treatment. In preclinical studies, UNITY has demonstrated that targeting BCL-xL with UBX1325 preferentially eliminated senescent cells from diseased tissue while sparing cells in healthy tissue. Multiple doses of UBX1325 are currently being evaluated in the ASPIRE Phase 2b study for people with DME who are not achieving optimal benefit from anti-VEGF drugs (NCT06011798). UNITY’s goal with UBX1325 is to transformationally improve real-world outcomes for patients with retinal disease. About UNITYUNITY is developing a new class of therapeutics to slow, halt, or reverse diseases of aging. UNITY’s current focus is on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases. More information is available at www.unitybiotechnology.com or follow us on X and LinkedIn. Forward-Looking StatementsThis press release contains forward-looking statements including statements related to UNITY’s understanding of cellular senescence and the role it plays in diseases of aging, the potential for UNITY to develop therapeutics to slow, halt, or reverse diseases of aging, including for ophthalmologic and neurologic diseases, UNITY’s expectations regarding potential benefits, activity, effectiveness, safety, and market opportunity of UBX1325, the potential for UNITY to successfully commence and complete clinical studies of UBX1325 for DME and other ophthalmologic diseases, the expected timing of results of the clinical trial in UBX1325, and UNITY’s expectations regarding the sufficiency of its cash runway. These statements involve substantial known and unknown risks, uncertainties, and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements, including risks related to delay or disruption in clinical trials, risks relating to the uncertainties inherent in the drug development process, risks relating to UNITY’s understanding of senescence biology, and risks related to UNITY’s ability to raise funding. This press release also contains data from third parties relating to market size and treatment outcomes, which involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. The Company may not actually achieve the plans, intentions, or expectations disclosed in its forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. The forward-looking statements in this press release represent our views as of the date of this release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this release. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general and the sufficiency of its cash runway, see UNITY’s most recent Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the Securities and Exchange Commission on April 22, 2025, as well as other documents that may be filed by UNITY from time to time with the Securities and Exchange Commission. Media ContactInizio Evoke CommsKatherine SmithKatherine.Smith@inizioevoke.com Investor ContactLifeSci Advisors, LLCJoyce Allairejallaire@lifesciadvisors.com

Phase 2Clinical Result

21 Apr 2025

·www.fiercepharma.com

FDA rejection of extended dosing interval is another piece of bad news for Regeneron’s Eylea HD

Regeneron’s struggles with high-dose Eylea have continued as the FDA has given a thumbs down to the company’s bid to stretch its maximum dosing frequency from 16 weeks to 24 weeks. At the J.P. Morgan Healthcare Conference in January, Regeneron CEO Leonard Schleifer said that the company’s new formulation of eye disease treatment Eylea needed “a few more arrows in its quiver,” to regain the edge in its competition with Roche’s Vabysmo.Three months later, one of those arrows has missed its target as the FDA has sent Regeneron a complete response letter (CRL), rejecting its bid to stretch the administration of high-dose Eylea from a maximum frequency of every 16 weeks to every 24 weeks.In a brief press release, Regeneron said the FDA "did not agree with Regeneron’s proposal to add additional extended dosing intervals,” offering no further explanation. The regulator did not specify any safety or efficacy issues, Regeneron said.“Regeneron is evaluating the FDA’s decision and will determine a path forward in due course,” the drugmaker added. The company is likely to provide more information in its quarterly earnings presentation on April 29.The New York company was hoping to give patients with wet age-related macular degeneration (AMD), diabetic macular edema (DME) and diabetic retinopathy (DR) an extended dosing option. Eylea HD can be administered at a maximum of every 16 weeks for AMD and DME and every 12 weeks for DR. A new dosing option would give Eylea HD a much-needed boost against Vabysmo, which can be administered every 16 weeks at a maximum. For both treatments, dosing regimens can be stretched after an initial period of monthly administration. The CRL came one day after the FDA accepted Regeneron’s application for Eylea HD to be approved for the treatment of macular edema following retinal vein occlusion (RVO) and for broadening the dosing schedule for Eylea HD to every four weeks across all approved indications. Currently, after a loading period, the drug can be given every 8 weeks at a minimum.These are two more potential “arrows” in Regeneron’s quiver as it attempts to regain the market share it has lost to Vabysmo.Playing catch-up has been problematic for Regeneron. In 2023, its approval for Eylea HD came two months late because of a manufacturing issue. Even after the nod, sales for the new formulation have been disappointing. In the last two quarters of 2024, for example, sales of Eylea HD declined from $392 million to $305 million. Since it was approved in early 2022 as a longer-acting answer to Eylea, Roche's Vabysmo sales has scaled up dramatically from 2.36 billion Swiss francs ($2.5 billion) in its first full year on the market to 3.86 billion Swiss francs ($4.2 billion) last year.Meanwhile, worldwide sales of Eylea—which are reported by Regeneron in the U.S. and by Bayer outside of the U.S.—have stagnated since reaching $9.4 billion in 2021. Last year, Eylea and Eylea HD generated combined revenue of $9.5 billion. Another concern for both Regeneron and Roche is the recent launch Amgen’s Eylea biosimilar Pavblu, which generated $31 million in sales in the six-plus weeks that it was on the market in the fourth quarter of last year. The impact of the threat will become more clear on May 1 when Amgen reports its first-quarter sales.

Drug Approval

20 Apr 2025

·endpts.com

FDA approves Dupixent for hives, rejects new Eylea dosing schedule

The FDA made two decisions on Regeneron’s best-selling drugs Friday, handing down one approval and one rejection. The approval came for Dupixent, the megablockbuster Regeneron develops and sells with Sanofi. Regulators approved it to treat chronic spontaneous urticaria, also known as chronic hives. The second decision was a rejection of a new dosing regimen for Eylea. Regeneron was attempting to extend the dosing interval for the 8 mg Eylea dose to up to every 24 weeks, across all of its approved indications. But the agency said it didn’t agree with pushing dosing beyond the maximum 16 weeks currently indicated. The company said in a press release it is determining its next steps for that effort. For Dupixent, Friday’s approval came after the FDA rejected Regeneron and Sanofi’s application for the label expansion in 2023, asking for an additional Phase 3 study. The new trial read out positively last year. Jennifer Maloney, Regeneron’s head of immunology, inflammation and infectious disease, told Endpoints News that the new study was designed to replicate the effects of an earlier, successful trial, which measured Dupixent’s effects in people who couldn’t get their hives under control using antihistamines. “Chronic spontaneous urticaria has quite complex etiology,” Maloney said. “You have some patients that will respond well to antihistamines alone. However, there are quite a lot of patients that really do not get full benefit. Which is why, often in practice, people will increase the doses beyond what’s typically approved.” Dupixent is already one of the top-selling drugs in the world, pulling in €13 billion ($14.8 billion) in sales last year. The new indication is seen as a key way to continue driving growth. Regeneron and Sanofi estimate that there are about 300,000 people over 12 years old who can’t control their hives with only antihistamine medications. The approval is one of the first few since the Trump administration’s broad cuts to US health agencies, including the FDA. But Maloney said she had not seen any difference in how the FDA is communicating for drugs under review. “We haven’t seen any consequences, despite all the media around this and understanding that there is turbulence right now,” Maloney said. “We’ve continued to have really great dialogue with the FDA.”

Drug ApprovalPhase 3

100 Deals associated with Aflibercept

External Link

KEGG	Wiki	ATC	Drug Bank
D09574	Aflibercept	L01XX44 S01LA05	DB08885

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Retinopathy of Prematurity	Japan	Bayer Yakuhin Ltd.	26 Sep 2022
Glaucoma, Neovascular	Japan	Bayer Yakuhin Ltd.	25 Mar 2020
Colorectal Cancer	Japan	Sanofi KK	30 Mar 2017
Diabetic Retinopathy	United States	Regeneron Pharmaceuticals, Inc.	25 Mar 2015
Macular Edema	Japan	Bayer Yakuhin Ltd.	22 Nov 2013
Retinal Vein Occlusion	European Union	Bayer AG	21 Nov 2012
Retinal Vein Occlusion	Iceland	Bayer AG	21 Nov 2012
Retinal Vein Occlusion	Liechtenstein	Bayer AG	21 Nov 2012
Retinal Vein Occlusion	Norway	Bayer AG	21 Nov 2012
Choroidal Neovascularization	Japan	Bayer Yakuhin Ltd.	28 Sep 2012
Macular Degeneration, Age-Related, 1	Japan	Bayer Yakuhin Ltd.	28 Sep 2012
Metastatic Colorectal Carcinoma	United States	Sanofi-Aventis U.S. LLC	03 Aug 2012
Diabetic macular oedema	Australia	Bayer Australia Ltd.	07 Mar 2012
Myopic choroidal neovascularization	Australia	Bayer Australia Ltd.	07 Mar 2012
Retinal vein occlusion-related macular edema	Australia	Bayer Australia Ltd.	07 Mar 2012
Wet age-related macular degeneration	United States	Regeneron Pharmaceuticals, Inc.	18 Nov 2011

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Edema	Phase 3	United States	Bayer AG	15 May 2023
Edema	Phase 3	China	Bayer AG	15 May 2023
Edema	Phase 3	Japan	Bayer AG	15 May 2023
Edema	Phase 3	Australia	Bayer AG	15 May 2023
Edema	Phase 3	Austria	Bayer AG	15 May 2023
Edema	Phase 3	Bulgaria	Bayer AG	15 May 2023
Edema	Phase 3	Czechia	Bayer AG	15 May 2023
Edema	Phase 3	Estonia	Bayer AG	15 May 2023
Edema	Phase 3	France	Bayer AG	15 May 2023
Edema	Phase 3	Georgia	Bayer AG	15 May 2023

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04707625 (CTgov)	Phase 4	Retinal Vein Occlusion	17	Aflibercept Ophthalmic	wltttqjdwe(zuzjixvljw) = pdlargxrxz xppuwdxiac (imbtsawbdk, 300.82) View more	-	24 Feb 2025
NCT04423718 (PULSAR, PipelineReview) Manual	Phase 3	Wet age-related macular degeneration	375	EYLEA HD® (aflibercept) Injection 8 mg	cfpakmycyc(alimdqvkde) = uxemdtmowv bdvuzmfigi (royczznyrr )	Positive	10 Feb 2025
NCT01652196 (CTgov)	Phase 2	Signet Ring Cell Carcinoma \| Mucinous Adenocarcinoma \| Rectal Adenocarcinoma ... View more	56	PET (positron emission tomography)+aflibercept+leucovorin+oxaliplatin+fluorouracil	mwgkqfypgi = gkbzeggogl zgcjvytnnv (gfmddcjths, ssokpzdsnh - exrkldjafu) View more	-	05 Feb 2025
JPRN-jRCTs011190006 (HGCSG1801, ASCO_GI2025) Manual	Phase 2	Metastatic Colorectal Carcinoma Second line	43	Aflibercept + FOLFIRI	upsdsurknu(kvzuozsrxt) = zxqqsfvkda nltmjfvwaj (xtsiwogexd, 45.8 - 72.1) View more	Positive	23 Jan 2025
NCT03939767 (XTEND, Pubmed \| Eye (Lond))	Not Applicable	Wet age-related macular degeneration	496	Intravitreal Aflibercept 2 mg	wnhzyqrpat(xwydgfnbfr) = wzgxuhfjoc wicuenssgh (mhrzcmjjtn, 2.0 - 4.9)	Positive	24 Dec 2024
NCT05850520 (QUASAR, GlobeNewswire \| Company_Website) Manual	Phase 3	Retinal vein occlusion-related macular edema	-	EYLEA HD 8 mg every 8 weeks after 3 initial monthly doses	mqaesivbea(ibxlumjxpa) = bwrvztvjma rxopsifdfv (unsotfsgqn ) View more	Non-inferior	17 Dec 2024
	Phase 3	Retinal vein occlusion-related macular edema	-	EYLEA HD 8 mg every 8 weeks after 5 initial monthly doses	mqaesivbea(ibxlumjxpa) = ildbukconh rxopsifdfv (unsotfsgqn ) View more	Non-inferior	17 Dec 2024
NCT04429503 (PHOTON, GlobeNewswire) Manual	Phase 3	Diabetic macular oedema	152	EYLEA HD® (aflibercept) Injection 8 mg every 12 weeks	dkyyroyczc(sqqkzycfff) = Patients switched to EYLEA HD experienced substantially slower fluid reaccumulation, as compared to their previous rate of fluid reaccumulation with EYLEA® (aflibercept) Injection 2 mg. xjshayqufa (etmxqlmhqq ) View more	Positive	18 Oct 2024
NCT04429503 (PHOTON, GlobeNewswire) Manual	Phase 3	Diabetic macular oedema	152	EYLEA HD® (aflibercept) Injection 8 mg every 16 weeks		Positive	18 Oct 2024
EURETINA2024 Manual	Not Applicable	Diabetic macular oedema	-	Ozurdexhasone implant (Ozurdex 0,7mg)	vawueazdwr(gjlsuwlfhr) = Although each group showed a significant decrease in CMT over time, no significant differences were observed between the two treatments at 6 months follow-up (p=0.337). mvjoxwrynx (yoolhvagnx ) View more	Positive	19 Sep 2024
PRECISE (EURETINA2024) Manual	Not Applicable	Age Related Macular Degeneration First line	1,039	afliberceptcept	cescxnxvsb(ihkctuopxq) = wyymmeqztx izizkkdulp (pkvvkfyvnr, 1.3 - 9.0) View more	Positive	19 Sep 2024
PRECISE (EURETINA2024) Manual	Not Applicable	Age Related Macular Degeneration First line	1,039	Placebo	cescxnxvsb(ihkctuopxq) = zsvgmnsotc izizkkdulp (pkvvkfyvnr, -8.7 to 5.2)	Positive	19 Sep 2024
EURETINA2024 Manual	Not Applicable	Age Related Macular Degeneration	102	Aflibercept	kzvnrtizrv(dngugugcdm) = vpyshmbqlo aeyfufsnxv (yxypmtcmtc ) View more	Positive	19 Sep 2024
EURETINA2024 Manual	Not Applicable	Age Related Macular Degeneration	102	Faricimab	kzvnrtizrv(dngugugcdm) = ruhnnvqxwf aeyfufsnxv (yxypmtcmtc ) View more	Positive	19 Sep 2024

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis